Quarterly ResultApr 29, 2026, 02:45 PM
IONS Q1 Revenue +87% to $246.1M; Net Loss $(92.5)M
AI Summary
IONIS PHARMACEUTICALS INC reported a significant increase in total revenue for Q1 2026, up 87% to $246.1 million, driven by strong product sales from TRYNGOLZA and DAWNZERA, and higher collaborative agreement revenue. The company also reduced its net loss by 37% to $(92.5) million, or $(0.56) per share. Key milestones were achieved with partners GSK, Otsuka, and Roche, contributing to research and development revenue.
Key Highlights
- Total revenue increased 87% to $246.1 million in Q1 2026 from $131.6 million in Q1 2025.
- Net loss decreased 37% to $(92.5) million, or $(0.56) per share, from $(146.9) million.
- Product sales, net, surged 583% to $43.0 million, including $27.1 million from TRYNGOLZA and $15.9 million from DAWNZERA.
- Research and development revenue grew 149% to $138.3 million, boosted by collaborative agreements.
- Received $30 million from GSK for bepirovirsen NDA/MAA acceptances in Japan and Europe.
- Received $15 million from Otsuka for DAWNZERA EU approval.
- Received $50 million from Roche for initiating a Phase 1 AD trial.
- Cash and cash equivalents decreased to $173.4 million, partly due to a $632.5 million escrow deposit for convertible notes.
Price Impact
More from IONS